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Abstract: Mitogen-activated protein kinases (MAPKs) are a family of protein kinases that function
as key signal transducers of a wide spectrum of extracellular stimuli, including growth factors
and pro-inflammatory cytokines. Dysregulation of the extracellular signal-regulated kinase (ERK)
MAPK pathway is associated with human skeletal abnormalities including Noonan syndrome,
neurofibromatosis type 1, and cardiofaciocutaneous syndrome. Here, we demonstrate that ERK
activation in osteoprogenitors is required for bone formation during skeletal development and
homeostasis. Deletion of Mek1 and Mek2, kinases upstream of ERK MAPK, in osteoprogenitors
(Mek1OsxMek2−/−), resulted in severe osteopenia and cleidocranial dysplasia (CCD), similar to
that seen in humans and mice with impaired RUNX2 function. Additionally, tamoxifen-induced
deletion of Mek1 and Mek2 in osteoprogenitors in adult mice (Mek1Osx-ERTMek2−/−) significantly
reduced bone mass. Mechanistically, this corresponded to decreased activation of osteoblast master
regulators, including RUNX2, ATF4, and β-catenin. Finally, we identified potential regulators of
osteoblast differentiation in the ERK MAPK pathway using unbiased phospho-mass spectrometry.
These observations demonstrate essential roles of ERK activation in osteogenesis and bone formation.
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1. Introduction
Homeostasis in the skeletal system is maintained by coupling between bone-forming osteoblasts
and bone-resorbing osteoclasts through a process of continual remodeling. Regulation of the anabolic
component of this homeostasis occurs through the controlled hierarchical differentiation of skeletal stem
cells, osteoprogenitors, and mature osteoblasts [1]. A number of critical signaling pathways, such as
transforming growth factor-beta (TGFβ)/bone morphogenic protein (BMP) signaling, wingless-type
MMTV integration site (WNT) signaling, and fibroblast growth factors (FGFs), regulate the lineage
commitment of skeletal stem cells to osteoprogenitors and subsequent maturation of osteoprogenitors
to osteoblasts [2].
As important mediators of cellular signaling, mitogen-activated protein kinases (MAPKs) are
evolutionally-conserved serine/threonine kinases that regulate diverse cellular functions including
cell proliferation, differentiation, and apoptosis [3]. MAPKs are part of a phospho-relay system in
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which the MAPK is phosphorylated and activated by an MAP2K that is, in turn, phosphorylated
and activated by an MAP3K. MAPKs are also dynamically regulated by accessory proteins, such as
scaffolds and phosphatases. This complexity allows MAPK pathways to serve diverse tissue-specific
functions including skeletal development and homeostasis [3–7].
The canonical extracellular signal-regulated kinase (ERK) MAPKs have two isoforms,
ERK1 (MAPK3) and ERK2 (MAPK1), both of which are highly expressed in osteoblast-lineage cells.
ERK1 and ERK2 MAPKs are activated by MAP2K MEK1 (MAP2K1) and MEK2 (MAP2K2) through
phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively [8–10].
Several studies have shown that the ERK MAPK pathway promotes osteoblast differentiation and bone
formation in vitro and in vivo [11–13]. Accordingly, mice lacking Erk1 and Erk2 in the limb and head
mesenchyme (Erk1−/−Erk2Prx1) display severe limb deformity and impaired skeletal mineralization [14].
Similarly, mice expressing a dominant-negative mutant of the Map2k Mek1 in mature osteoblasts exhibit
hypomineralization of clavicle and calvaria [5], similar to cleidocranial dysplasia (CCD) seen in human
patients with loss-of-function mutations in RUNX2 or mice with Runx2 haploinsufficiency [15,16].
Our data demonstrate that ERK activation in osteoprogenitors is required for osteoblast
differentiation and bone formation via control of osteoblast master regulators including RUNX2,
ATF4, and β-catenin. We generated mice lacking Mek1 and Mek2 in osteoprogenitors (Mek1OsxMek2−/−)
by crossing mice with a conditional deletion of Mek1 in osteoprogenitors (Mek1Osx) and mice with a
germline deletion of Mek2 (Mek2−/−), demonstrating that inactivation of ERK in osteoprogenitors results
in severe bone loss in both axial and appendicular bones along with characteristic CCD phenotypes.
Likewise, inducible, postnatal deletion of Mek1 and Mek2 in osteoprogenitors (Mek1Osx-ERTMek2−/−)
significantly reduced bone mass, suggesting that ERK activation in osteoprogenitors is important for
bone formation during skeletal homeostasis. Finally, unbiased phospho-mass spectrometry using the
post translational modification (PTM) scan direct technology was performed in Mek1/2-sufficient and
-deficient osteoblasts to identify potential ERK MAPK substrates important for osteoblast differentiation.
Future work will be needed to explore the roles of these putative ERK substrates in osteogenesis and
bone formation.
2. Results
2.1. The ERK MAPK Pathway is Highly Activated in Osteoblasts In Vitro and In Vivo
To examine ERK activation in osteoblasts in vivo, immunohistochemistry was performed for
phosphorylation of ERK1/2 in the femur of eight-week-old mice (Figure 1A). Phosphorylated ERKs
were mainly detected in the trabecular bone area under the growth plate that has a high bone
remodeling activity. Specifically, ERK1/2 were highly phosphorylated in osteoblasts on the bone
surface, while osteocytes within the bone matrix showed modest phosphorylation of ERK1/2,
suggesting dynamic ERK activation in osteoblast-lineage cells at different differentiation stages
in vivo (Figure 1A). To test this hypothesis, we examined the kinetics of ERK phosphorylation during
osteoblast differentiation in vitro (Figure 1B). Primary calvarial osteoblasts (COBs, osteoprogenitor)
were isolated from mouse calvaria at Postnatal Day 5 (P5), cultured under osteogenic conditions for
21 days, and phosphorylation of ERK1/2 at different osteoblast differentiation stages was assessed by
immunoblotting. Phosphorylation levels of ERK peaked at Day 12 of osteogenic culture and gradually
decreased during later differentiation stages, demonstrating that ERK is highly activated in mature
osteoblasts. Thus, these results suggest that ERK activation plays a role in osteoblast differentiation
and function in vivo and in vitro.
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Figure 1. ERK activation in osteoblasts in vitro and in vivo. (A) Immunohistochemistry for   
phospho‐ERK1/2 was performed in the femur of eight‐week‐old male mice. TB, trabecular bone; CB, 
cortical bone; BM; bone marrow. Scale bar, 500 μm (left) and 100 μm (right). (B) Primary calvarial 
osteoblasts  (COBs)  were  isolated  from  mouse  calvaria  at  Postnatal  Day  5  and  cultured  under 
osteogenic conditions. Phosphorylation of ERK1/2 was determined by immunoblotting with   
anti‐P‐ERK1/2 antibody. ERK1/2 was used as a loading control. 
2.2. Inactivation of ERK in Osteoprogenitors Causes Severe Osteopenia and Cleidocranial Dysplasia 
To investigate the role of the ERK MAPK pathway in osteoblasts in vivo, mice lacking Mek1 and 
Mek2, mitogen‐activated protein kinase kinases  (MAP2Ks) upstream of ERK,  in osteoprogenitors 
were generated by crossing mice harboring a floxed allele of Mek1 (Mek1fl/fl) with Osx‐Cre [17,18] in 
the Mek2‐germline null background (Mek2−/−) [19,20]. Immunoblotting analysis validated deletion of 
Mek1  and Mek2  in  the  calvarium  of P5 Mek1OsxMek2−/−  neonates  (Figure.  2A). While  no  obvious 
Figure 1. ERK activation in osteoblasts in vitro and in vivo. (A) Immunohistochemistry for phospho-
ERK1/2 was performed in the femur of eight-week-old male mice. TB, rab cular bone; CB, cortical
bone; BM; bone marrow. Scale bar, 500 µm (left) and 100 µm (right). (B) Primary calvarial osteoblasts
(COBs) were isolated from mouse calvaria at Postnatal Day 5 and cultured under osteogenic conditions.
Phosphorylation of ERK1/2 was determined by immunoblotting with anti-P-ERK1/2 antibody. ERK1/2
was used as a loading control.
2.2. Inactivation of ERK in Osteoprogenitors Causes Severe Osteopenia and Cleidocranial Dysplasia
To investigat the role of the ERK MAPK pathwa i osteobla ts in vivo, mi e lacking Mek1 and
Mek2, mitogen-activated protein kinase kinases (MAP2Ks) upstream of ERK, in ost enitors were
generated by crossing mice harboring a floxed allele of Mek1 (Mek1fl/fl) with Osx-Cre [17,18] in the
Mek2-germline null background (Mek2−/−) [19,20]. Immunoblotting analysis validated deletion of
Mek1 and Mek2 in the calvarium of P5 Mek1OsxMek2−/− neonates (Figure. 2A). While no obvious
skeletal phenotypes were observed in mice with a deletion of Mek1 (Mek1Osx) or Mek2 (Mek2−/−)
alone, Mek1OsxMek2−/− mice displayed severe growth retardation and skeletal defects and died
at approximately four weeks old (Figure 2B). Mek1OsxMek2−/− mice were born at the expected
Mendelian ratio. Skeletal preparations using Alizarin red/Alcian blue staining and microCT analysis of
three-week-old Mek1OsxMek2−/−mice showed multiple rib fractures (Figure 2C), hypoplasia of the hyoid
bone and clavicle (Figure 2D,E), and hypomineralization of the calvarium (Figure 2F). These phenotypes
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resemble those seen in human and murine cleidocranial dysplasia (CCD), characterized by open
fontanelles, hypoplastic clavicles, and short stature [15,16]. Additionally, microCT analysis was
performed in the femurs of WT, Mek1Osx, Mek2−/−, and Mek1OsxMek2−/− mice to assess bone mass
(Figure 3A,B). While bone mass in Mek2−/− femurs was comparable to that in wildtype femurs,
Mek1Osx femurs displayed a modest decrease in trabecular bone mass and midshaft cortical thickness.
When Mek1 and Mek2 were both deleted in osteoprogenitors, femoral trabecular bone mass, number,
and thickness in addition to cortical thickness were all significantly reduced, demonstrating severe
osteopenia (Figure 3A,B). Accordingly, expression of osteoblast differentiation genes, including alkaline
phosphatase (Alpl), osteocalcin (Bglap), osterix (Sp7), bone sialoprotein (Ibsp), and type 1 collagen α1
(Col1a1), was markedly decreased relative to WT femurs (Figure 3C). Histological analysis demonstrated
that trabecular bone mass and cortical thickness were both reduced in Mek1OsxMek2−/− femurs,
while bone marrow was filled with hypertrophic chondrocytes, suggesting delayed endochondral
ossification and impaired osteoclast-mediated remodeling of the growth plate due to impaired
expression of the Rank ligand (Figure 3D). Finally, serum levels of the bone formation marker,
procollagen type I N-terminal propeptide (P1NP), and the bone resorption marker, C-terminal
telopeptide of type I collagen (CTx-I), were measured in Mek1OsxMek2−/− mice, demonstrating a
decrease in bone formation activity without any alteration in bone resorption activity (Figure 3E and
F). Notably, these skeletal defects seen in Mek1OsxMek2−/− mice are more severe than those in mice
with Runx2 haploinsufficiency [15], suggesting that the ERK MAPK pathway has additional functions
beyond RUNX2 regulation in osteoblasts. Taken together, ERK activation in osteoprogenitors is critical
for skeletal development during the early postnatal stage.
2.3. Inducible Inactivation of the ERK Pathway in Osteoprogenitors Results in Osteopenia in Adult Mice
To investigate the role of ERK activation in bone formation during later postnatal life, we generated
an inducible, osteoblast-specific Mek1/2-knockout by crossing Mek1fl/fl mice with osterix-CreERT mice
expressing a tamoxifen-inducible Cre recombinase in osteoprogenitors in the Mek2-germline null
background (Mek1Osx-ERTMek2−/−) [21]. Eight-week-old Mek1fl/flMek2−/− and Mek1Osx-ERTMek2−/− mice
were treated with tamoxifen for five consecutive days to induce Cre-mediated deletion of Mek1 in
osteoprogenitors, and nine weeks later, skeletal phenotypes were assessed by microCT (Figure 4A).
Similar to Mek1OsxMek2−/− mice, trabecular bone mass, number, and thickness and midshaft cortical
thickness were markedly reduced in Mek1Osx-ERTMek2−/− mice relative to those in Mek1fl/flMek2-/- mice
(Figure 4B,C), demonstrating that ERK activation in osteoprogenitors is also important for bone
formation during skeletal homeostasis.
2.4. The ERK MAPK Pathway Is Important for Activation of Osteoblast Master Regulators
Our finding that inactivation of ERK in osteoprogenitors causes CCD phenotypes in mice implies
that ERK plays a critical role in the regulation of RUNX2 in osteoblasts (Figure 2). Accordingly,
a previous study has demonstrated that ERK1/2-mediated phosphorylation of RUNX2 at Ser319
is required for RUNX2 transcriptional activity and osteoblast differentiation [22]. In addition to
RUNX2, two key regulators of osteoblast differentiation, ribosomal s6 kinase 1/2 (RSK1/2) that regulates
ATF4 transcription activity [23,24] and GSK3β that regulates β-catenin stability [25–27], have been
also reported as ERK substrates. To examine the ability of ERK to activate these regulators in
osteoblasts, Mek1- and Mek2-deficient osteoblasts (∆Mek1/2) were generated by deleting Mek1 in
primary Mek1fl/flMek2−/− COBs via lentivirus-mediated delivery of Cre recombinase. WT and ∆Mek1/2
COBs were cultured under osteogenic conditions, and phosphorylation levels of RUNX2 (Ser319),
RSK1/2 (Ser380), and GSK3β (Ser9) were assessed by immunoblotting (Figure 5A,B). In WT COBs,
phosphorylation of MEK1, RUNX2, and RSK1/2 peaked at Day 6 of osteogenic culture, but were all
markedly reduced in the absence of Mek1/2 (∆Mek1/2) (Figure 5A). Intriguingly, ∆Mek1/2 COBs showed
a significant decrease in protein levels of β-catenin at Days 9 and 15 of osteogenic culture, while the
kinetics of GSK3β phosphorylation in ∆Mek1/2 COBs were comparable to those in wildtype COBs
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(Figure 5B), suggesting that ERK-mediated mechanisms independent of GSK3β phosphorylation are
responsible for β-catenin stability in osteoblasts. These results are consistent with luciferase assays
showing that the transcriptional activities of RUNX2 (OG2-luc), β-catenin (TopFlash-luc), and ATF4
(OSE1-luc) were all markedly decreased in ∆Mek1/2 COBs (Figure 5C). Thus, the ERK MAPK pathway
is critical for activation of RUNX2, β-catenin, and ATF4 in osteoblasts.
Int. J. Mol. Sci. 2019, 20, x  5  of  15 
 
 
Figure 2. Inactivation of ERK in osteoprogenitors causes cleidocranial dysplasia (CCD) in mice.   
(A) Protein levels of Mek1 and Mek2 in the calvarium of WT and Mek1OsxMek2−/− neonates at Postnatal 
Day 5 (B–E) Alizarin red/Alcian blue staining of skeletal preparations of three‐week‐old WT, Mek1Osx, 
Mek2−/−, and Mek1OsxMek2−/− mice. The  representative whole body  images are displayed  (B,C). The 
arrows indicate rib fractures in Mek1OsxMek2−/− mice (C, right). Hyoid bone (D) and clavicle (E) were 
also displayed. (F) MicroCT analysis shows representative 3D‐reconstruction images of three‐week‐
old WT, Mek1Osx, Mek2−/−, and Mek1Osx Mek2−/− calvaria. The arrows indicate hypomineralization areas. 
Figure 2. Inactivation of ERK i steoprogenitors causes cleidocranial dysplasia (CCD) in mice.
(A) Protein levels of Mek1 and Mek2 in the calvarium of WT and Mek1O ek2 /− neonates at Postnatal
Day 5 (B–E) Alizarin red/Alcian blue staining of skeletal preparations of three-week-old WT, Mek1Osx,
Mek2−/−, and Mek1OsxMek2−/− mice. The representative whole body images are displayed (B,C).
The arrows indicate rib fractures in Mek1OsxMek2−/−mice (C, right). Hyoid bone (D) and clavicle (E) were
also displayed. (F) MicroCT analysis shows representative 3D-reconstruction images of three-week-old
WT, Mek1Osx, Mek2−/−, and Mek1Osx Mek2−/− calvaria. The arrows indicate hypomineralization areas.
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Figure 3. Inactivation of ERK in osteoprogenitors causes severe osteopenia in long bones.   
(A,B)  MicroCT  analysis  of  three‐week‐old  WT,  Mek1Osx,  Mek2−/−,  and  Mek1OsxMek2−/−  femurs. 
Representative  3D‐reconstruction  images  of  trabecular  (upper)  and  cortical  bone  (lower)  are 
displayed  (A). Quantification  of  trabecular  bone mass  and midshaft  cortical  bone  thickness  are 
displayed (B). Trabecular bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular 
number per cubic millimeter (Tb.N), and cortical  thickness  (C.Th). (n = 4~5).  (C) Total RNAs were 
isolated  from  three‐week‐old  WT  and  Mek1OsxMek2−/−  tibias,  and  mRNA  levels  of  osteoblast 
differentiation genes were measured by RT‐PCR. (n = 6). (D) H&E‐stained  longitudinal sections of 
three‐week‐old WT and Mek1OsxMek2−/− femurs. Scale bar, 1 mm. (E,F) Serum levels of P1NP and   
CTx‐I were measured by ELISA. (n = 5). Values represent the mean ± SD.; NS, not significant, *p < 0.05, 
**p < 0.01, ***p < 0.001, and ****p < 0.0001 by the one‐way ANOVA test (B) or an unpaired two‐tailed 
Student’s t‐test (C,E,F). 
2.3. Inducible Inactivation of the ERK Pathway in Osteoprogenitors Results in Osteopenia in Adult Mice 
Figure 3. Inactivation of ERK in osteoprogenitors causes severe osteopenia in long bones.
(A,B) MicroCT an lysis of three-week-old WT, Mek1Osx, Mek2−/−, and Mek1OsxMek2−/− femurs.
Representative 3D-reconstruction images of trabecular (upper) and cortical bone (lower) ar displayed
(A). Quantification of trabecular bone ss and midshaft cortical bone thickness are displayed (B).
Trabecular bone vol me/total volume (BV/TV), trabecular thickness (Tb.Th), trabecular number per
cub c millimeter (Tb.N), and cortical thickness (C.Th). (n = 4~5). (C) Total RNAs were isolated from
three-week-old WT and Mek1OsxMek2−/− tibias, and mRNA levels of osteoblast differen iation genes
were m asured by RT-PCR. (n = 6). (D) H&E-stained longitud nal sections of three-week-old WT and
Mek1OsxMek2−/− femurs. Scale b r, 1 mm. (E,F) Serum levels of P1NP and CTx-I were measured by
ELISA. (n = 5). Values represent the mean ± SD.; N , not significant, * p < 0.05, ** p < 0.01, *** p < 0.001,
and **** p < 0.0001 by the one-way ANOVA test (B) or an unpaired two-tailed Student’s t-test (C,E,F).
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To  investigate  the  role  of  ERK  activation  in  bone  formation  during  later  postnatal  life, we 
generated an inducible, osteoblast‐specific Mek1/2‐knockout by crossing Mek1fl/fl mice with   
osterix‐CreERT mice expressing a tamoxifen‐inducible Cre recombinase  in osteoprogenitors  in the 
Mek2‐germline null background (Mek1Osx‐ERTMek2−/−) [21]. Eight‐week‐old Mek1fl/flMek2−/− and   
Mek1Osx‐ERTMek2−/− mice were treated with tamoxifen for five consecutive days to induce Cre‐mediated 
deletion of Mek1  in osteoprogenitors, and nine weeks  later, skeletal phenotypes were assessed by 
microCT (Figure 4A). Similar to Mek1OsxMek2−/− mice, trabecular bone mass, number, and thickness 
and midshaft cortical thickness were markedly reduced in Mek1Osx‐ERTMek2−/− mice relative to those in 
Mek1fl/flMek2‐/‐ mice  (Figure  4B,C),  demonstrating  that  ERK  activation  in  osteoprogenitors  is  also 
important for bone formation during skeletal homeostasis. 
 
Figure 4. Inducible inactivation of ERK in osteoprogenitors decreases bone mass in adult mice. (A) A 
diagram of the strategy for tamoxifen‐induced deletion of Mek1 and Mek2 in osteoprogenitors.   
(B,C) MicroCT analysis of 17‐week‐old male WT and Mek1Osx‐ERTMek2−/− femurs. 3D‐reconstruction 
Figure 4. Inducible inactivation of ERK i t it rs decreases bone mass in adult mice.
(A) A diagram of the strategy for tamoxife -induced deleti n of Mek1 and Mek2 in oste progenitors.
(B,C) MicroCT analysis of 17-week-old male WT and Mek1Osx-ERTMek2−/− femurs. 3D-reconstruction
images (B) and quantification (C) are displayed. Trabecular bone volume/total volume (BV/TV),
trabecular thickness (Tb.Th), trabecular number per cubic millimeter (Tb.N), and cortical thickness
(C.Th). (n = 5~6). Scale bar, 500 µm. Values represent mean ± SD.; * p < 0.05 and ** p < 0.01 by an
unpaired two-tailed Student’s t-test (C).
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Figure 5. The MEK‐ERK pathway is important for activation of osteoblast master regulators.   
(A,B)  Primary WT  and  ∆Mek1/2  COBs were  cultured  under  osteogenic  conditions  and  lysed  at 
different time points. Phosphorylation levels of RUNX2 (Ser319) and MEK1 (A) and GSK3β (Ser9) and 
RSK1/2  (Ser380)  (B) and protein  levels of β‐catenin  (B) were assessed by  immunoblotting with  the 
indicated antibodies. (C) Primary WT and ∆Mek1/2 COBs were transfected with OG2‐luc (RUNX2), 
TopFlash‐luc  (Wnt/β‐catenin), or OSE1‐luc  (ATF4)  reporter genes along with Renilla. Twenty  four 
hours after transfection, luciferase activity was measured and normalized to Renilla.   
(D)  Experimental  strategy  to  identify  proteins  differentially  phosphorylated  in WT  and  ∆Mek1/2 
COBs. (E) Enrichment plots (left) and gene signature sets (right) in WT and ∆Mek1/2 COBs. Gene‐set 
Figure 5. The MEK-E pathway is important for activation of osteoblast master regulators.
(A,B) Primary WT and ∆Mek1/2 COBs were cultured under osteogenic conditions and lysed at
different time points. Phosphorylation levels of RUNX2 (Ser319) and MEK1 (A) and GSK3β (Ser9)
and RSK1/2 (Ser380) (B) and protein levels of β-catenin (B) were assessed by immunoblotting with the
indicated antibodies. (C) Primary WT and ∆Mek1/2 COBs were transfected with OG2-luc (RUNX2),
TopFlash-luc (Wnt/β-catenin), or OSE1-luc (ATF4) reporter genes along with Renilla. Twenty four
hours after transfection, luciferase activity was measured and normalized to Renilla. (D) Experimental
strategy to identify proteins differentially phosphorylated in WT and ∆Mek1/2 COBs. (E) Enrichment
plots (left) and gene signature sets (right) in WT and ∆Mek1/2 COBs. Gene-set enrichment analysis
(GSEA) analysis displays enrichment of genes involved in SHP2 and the FGF signaling pathway.
Values represent mean ± SD.; ** p < 0.01 by an unpaired two-tailed Student’s t-test (C).
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To identify novel regulators of osteoblast differentiation in the ERK MAPK pathway, unbiased
phospho-mass spectrometry using the post translational modification (PTM) scan direct technology was
performed in WT and ∆Mek1/2 COBs (Figure 5D). Three days after osteogenic culture, cell lysates were
immunoprecipitated using a mixture of antibodies specific to phosphorylated proteins regulated by
MAPK, CDK, PKA, AKT, and AMPK, and the immunoprecipitates were subjected to mass spectrometry.
Gene-set enrichment analysis (GSEA) using the intensity of identified proteins showed an enrichment
of phosphorylated proteins in the pathways of SHP2 (encoded by Ptpn11), FGF (fibroblast growth
factor), and SCF-KIT (stem cell factor-kit) in WT COBs, and that phosphorylation of the proteins in
these pathways was markedly decreased in ∆Mek1/2 COBs (Figure 5E and Supplementary Figure S1).
The protein-tyrosine phosphatase SHP2 has been known to function upstream of MEK1/2 MAP2Ks and
to be important for osteoblast maturation [28]. Additionally, FGF signaling activates the ERK MAPK
pathway and functions as a key regulator of osteoblast differentiation and skeletal development [12,29].
Finally, the SCF-KIT pathway is found to protect osteoblasts from oxidative stress through activating
c-Kit-AKT signaling [30]. However, further study is needed to understand the contribution of these
pathways to the overall functions of the ERK pathway in osteoblasts.
3. Discussion
In this study, we demonstrated that the ERK MAPK pathway is required for bone formation during
skeletal development and homeostasis. Inactivation of ERK in osteoprogenitors (Mek1OsxMek2−/−) at an
early postnatal stage of skeletal development results in severe osteopenia and CCD phenotypes.
Similarly, inducible, postnatal inactivation of ERK in osteoprogenitors (Mek1Osx-ERTMek2−/−)
significantly decreased bone mass. These results suggest that ERK activation plays a critical role in both
skeletal development and homeostasis. Mechanistically, this corresponded to decreased activation of
RUNX2, WNT/β-catenin, and RSK-ATF4 signaling pathways. Furthermore, unbiased phospho-mass
spectrometry was performed to identify potential new regulators of osteoblast differentiation in the
ERK MAPK pathway.
The ERK MAPK pathway has been implicated as a positive regulator for osteoblast differentiation
and bone formation [11,13,14]. A previous study has demonstrated that dominant-negative Mek1
expression in osteoblasts results in CCD in mice, while constitutively-active Mek1 expression in
osteoblasts partially rescues CCD phenotypes caused by Runx2 haploinsufficiency [5], suggesting
that the MEK-ERK MAPK pathway regulates RUNX2 in osteoblasts. Consistent with this study,
CCD phenotypes were also observed in mice lacking Mek1 and Mek2 in osteoprogenitors
(Mek1OsxMek2−/−) (Figure 2). Additionally, Mek1OsxMek2−/− mice showed delayed ossification of
long bones along with increased number of hypertrophic chondrocytes (Figure 3D), a phenotype
similar to that seen in Erk1−/−Erk2Osx mice [31].
ERK has several other known substrates besides RUNX2 that contribute to osteogenesis including,
RSK2 [23]. RSK2 phosphorylates and activates the transcription factor ATF4, which is required for
procollagen gene transcription in the later stages of osteoblast differentiation [24]. Additionally,
ERK interacts with a wide range of parallel signal-transduction pathways in osteoblasts, such as
the WNT/β-catenin pathway. ERK-mediated phosphorylation of GSK3β at Ser9 decreases its kinase
activity, resulting in β-catenin accumulation through a reduction in ubiquitin-mediated proteasomal
degradation [27]. Our data demonstrate that inactivation of ERK in osteoblasts leads to a significant
decrease in the phosphorylation of RUNX2 and RSK2 and the corresponding transcriptional activity
of RUNX2 and ATF4 (Figure 5A–C). Intriguingly, while GSK3β phosphorylation was not altered in
the absence of Mek1 and Mek2, ∆Mek1/2 COBs displayed a substantial decrease in protein levels and
transcription activity of β-catenin, implicating additional ERK-mediated mechanisms that regulate
β-catenin stability in osteoblasts.
Our unbiased phospho-mass spectrometry revealed a high enrichment of phosphorylated proteins
in the pathways of SHP2, FGF, and SCF-KIT in WT COBs, and that phosphorylation of the proteins in
these pathways was markedly decreased in ∆Mek1/2 COBs. Among these proteins, phosphorylation of
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a member of the FOS family, FRA2 (FOSL2) [32], was substantially reduced in the absence of Mek1 and
Mek2. FRA2 is important for skeletal mineralization, as overexpression of Fra2 (Fosl2) in transgenic
mice increased bone formation, though understanding the mechanism regulating FRA2 in osteoblasts
requires further study [33]. Our data identified potential regulators of osteogenic differentiation and
bone formation and will thereby improve understanding of ERK-mediated molecular mechanisms in
osteogenesis and bone-related disease.
4. Materials and Methods
4.1. Antibodies and Cell Culture
Antibodies specific to phospho-ERK1/2 (Cell Signaling, 4376, Danvers, MA, USA), ERK2
(Cell Signaling, 4195), phospho-MEK1 (Cell Signaling, 9127), β-catenin (Cell Signaling, 9587),
phospho-RSK1/2 (Santa Cruz, sc-12898, Santa Cruz, CA, USA), phospho-GSK3β (Cell Signaling,
9323), and GAPDH (Santa Cruz, sc-25778) were used according to the manufacturer’s instructions.
Phospho-RUNX2 (Ser319) antibody was generated as previously described [34].
To generate ∆Mek1/2 osteoblasts, primary calvarial osteoblasts (COBs) were isolated from
calvaria of 5-day-old MEK1fl/flMEK2−/− neonates using collagenase type II (50 mg/mL, Worthington,
LS004176)/dispase II (100 mg/mL, Roche, 10165859001, Mannheim, Germany), transduced with
lentiviruses expressing cre-recombinase, and selected with puromycin. COBs were maintained in
α-MEM medium (Gibco, Grand Island, NY, USA) containing 10% FBS (Corning, Corning, NY, USA),
2 mM L-glutamine (Corning), 1% penicillin/ streptomycin (Corning), and 1% nonessential amino acids
(Corning) and differentiated with ascorbic acid (200 µM, Sigma, A8960, Saint Louis, MO, USA) and
β-glycerophosphate (10 mM, Sigma, G9422).
4.2. Mice
Mek1fl/fl mice and Mek2−/− mice were generated as previously reported, respectively [19,35],
and maintained in a 129/SvEv background. To generate osteoprogenitor-specific double knockout
(Mek1OsxMek2−/−), mice were crossed with Osx-cre [17,18], and littermate control was used for all skeletal
analyses. To generate mice harboring inducible deletion of Mek1 in osteoprogenitors, Mek1fl/flMek2−/−
mice were crossed with Osterix-CreERT [21]. For postnatal activation of CreERT, 75 mg/kg of tamoxifen
(Sigma, T5648) in corn oil (Sigma) were intraperitoneally injected into 8-week-old mice once a day for
five consecutive days. All animals including Mek1-floxed mice and Mek2 knockout mice were used
in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were handled
according to the animal protocol approved by the University of Massachusetts Medical School on
animal care (IACUC).
4.3. MicroCT and Skeletal Preparation
MicroCT was used for qualitative and quantitative assessment of trabecular and cortical bone
microarchitecture and performed by an investigator blinded to the genotypes of the animals under
analysis. Femurs excised from the indicated mice were scanned using a microCT 35 (Scanco Medical,
Brüttisellen, Switzerland) with a spatial resolution of 7 µm. Briefly, trabecular bone mass of the distal
femur was measured in an upper 2.1-mm region beginning 280 µm proximal to the growth plate,
and cortical bone thickness was measured in a midshaft region of 0.6 mm in length. MicroCT analysis
of 3-week-old skulls was performed at isotropic voxel sizes of 12 µm. 3D reconstruction images were
generated from contoured 2D images using microCT software (Brüttisellen, Switzerland). Alternatively,
the Inveon multimodality 3D visualization program was used to generate fused 3D views of multiple
static or dynamic volumes of microCT modalities (Siemens Medical Solutions USA, Inc., Norwood,
MA, USA). All images presented are representative of the respective genotypes (n > 4).
For skeletal preparation, mice were skinned, eviscerated, and fixed in 95% EtOH for a day, and the
skeletons were transferred in acetone for 2 days. Then, skeletons were stained with 0.1% of Alizarin red
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s and 0.3% of Alcian blue (Sigma, A3157) solution for 3 days as previously described [36]. After staining,
samples were washed with 95% EtOH, and soft tissue was cleared by a 1.5% KOH solution. Soft tissue
was subsequently further cleared in 1% KOH. All images presented are representative of the respective
genotypes (n > 5).
4.4. Histology and Immunohistochemistry
For histological analysis, 3- or 8-week-old femurs were fixed in 10% neutral formalin at 4 ◦C for
2 days and then decalcified in 15% tetrasodium EDTA (pH 8.0) at 4 ◦C for 2 weeks. Tissues were
dehydrated in different concentrations of EtOH, incubated in xylene, and embedded in paraffin. Paraffin
sections were performed at a 7-µm thickness along the coronal plate and stained with hematoxylin and
eosin (H&E).
For immunohistochemistry, longitudinal sections of 8-week-old femurs were stained with
anti-phospho-ERK1/2 antibody (Cell Signaling, 4376). Briefly, after deparaffinization and rehydration,
paraffin tissue sections were blocked with 3% goat serum, 1% BSA, 0.1% Triton X-100 in PBS for 1 h at
room temperature, incubated with primary antibody specific to phospho-ERK1/2 overnight at 4 ◦C,
followed by TSA-biotin (Perkin Elmer, Waltham, MA, USA) and streptavidin-HRP, and then visualized
with 2,2′-diaminobenzidine tetrahydrochloride as per the manufacturer’s instructions.
4.5. RT-PCR and Immunoblotting
Total RNAs were purified using QIAzol (Qiagen, Germantown, MA, USA), and cDNA was
synthesized using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Beverly,
MA, USA). Quantitative RT-PCR was performed using SYBR® Green PCR Master Mix (Bio-Rad,
Hercules, CA, USA) with the Bio-Rad CFX Connect Real-Time PCR detection system. The primers
used for PCR are described in the Supplementary Table S1.
For immunoblotting, cells were lysed in TNT lysis buffer (50 mM Tris, 50 mM NaCl, 1% Triton
X-100, 1 mM EDTA, 10 mM NaF, proteinase inhibitor cocktails (Sigma, P8340)), subjected to SDS-PAGE,
and transferred to Immobilon-P membranes (Millipore, Burlington, MA, USA). After incubation with a
blocking buffer (5% skim milk in TTBS buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20),
the membranes were treated with the indicated antibodies, incubated with HRP-conjugated secondary
antibodies, and developed with ECL (Thermo Scientific, Waltham, MA, USA). Anti-GAPDH antibody
was used as a loading control.
4.6. Luciferase Reporter Assay
WT and ∆Mek1/2 COBs were transfected with the RUNX2-responsive reporter gene (OG2-luc),
β-Catenin-responsive reporter gene (TopFlash-luc), or ATF4-responsive reporter gene (OSE1-luc) with
the Renilla luciferase vector (Promega, Madison, WI, USA) using the Effectene transfection reagent
(Qiagen). Twenty four hours after transfection, the dual luciferase assay was performed according to
the manufacturer’s protocol (Promega), and luciferase activity was normalized to Renilla.
4.7. Phospho-Mass Spectrometry-Based Antibody Enrichment
Post translational modification (PTM) scan direct technology from Cell Signaling Technology
(CST, Danvers, MA, USA) was performed in WT and ∆Mek1/2 COBs to identify phosphorylated
proteins regulated by ERK. Briefly, two sets of WT and ∆Mek1/2 COBs were cultured under
osteogenic conditions for 3 days. Cell extracts were incubated with an antibody mixture
(Phospho-Akt/AMPK/MAPK/CDK/PKA Substrate Motif Antibodies Mix, Cell Signaling, 9614/10001/
759/2325/9624, respectively) and antibodies were immobilized to protein A (or G) agarose.
After immunoprecipitation, eluted proteins were analyzed by LC-MS/MS using LTQ-Orbitrap-Velos,
ESI-CID. PTM scan results in WT and ∆Mek1/2 COBs are shown in Supplementary Table S2.
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4.8. Gene Set Enrichment Analysis
Proteins with more than two unique peptides derived from the parent ion intensity were defined
as qualified proteins for GSEA analysis. Gene sets from the Broad Institute Molecular Signatures
Database were used, and multiple lists of enriched gene sets were generated using the GSEA algorithm
as previously described [37]. Enrichment for up-/down-regulated proteins in ∆Mek1/2 COBs was
assessed against a rank list of all the available expression values from ∆Mek1/2 COBs to expression
from WT COBs. The permutation type was set to phenotype, and other settings were set as default.
A nominal p-value <0.05 and FDR (false discovery rate) q-value <0.25 were considered as a significantly
enriched pathway.
4.9. Statistical Analysis
All data are shown as the mean ± standard deviation (SD). We first performed the Shapiro–Wilk
normality test for checking normal distributions of the groups. If normality tests passed, two-tailed,
unpaired Student’s t-tests, and if normality tests failed, Mann–Whitney tests were used for the
comparisons between two groups. To compare four groups, one-way ANOVA was used if normality
tests passed, and then Tukey’s multiple comparison test was used for all pairs of groups. Statistical
analysis was performed using the GraphPad PRISM software (v7.0a, La Jolla, CA, USA). p < 0.05 was
considered statistically significant. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
5. Conclusion
In this study, we demonstrated ERK MAPK pathway is required for skeletal development and bone
homeostasis through analysis of genetic deletion of ERK upstream, Mek1 and Mek2 in osteoprogenitors
in developmental stage (Mek1OsxMek2−/−) and postnatal stage (Mek1Osx-ERTMek2−/−). This study
strongly supports previous studies on ERK MAPK function in osteoblast differentiation and bone
formation, phenotypically and mechanistically. Moreover, unbiased phospho-mass spectrometry
provides putative downstream of ERK MAPK pathway in osteoblast differentiation and further study
will improve knowledge regarding the role of ERK MAPK in bone biology.
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